Aeglea BioTherapeutics, which is developing enzymes for rare genetic metabolic diseases and tumors, announced terms for its IPO on Monday.
The Austin, TX-based company plans to raise $60 million by offering 3.5 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Aeglea BioTherapeutics would command a fully diluted market value of $203 million.
Aeglea BioTherapeutics was founded in 2013 and booked $6 million in grant revenue for the 12 months ended December 31, 2015. It plans to list on the Nasdaq under the symbol AGLE. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities are the joint bookrunners on the deal. It is expected to price during the week of April 4, 2016.
